Option chain shows key data for Mountain Lake Acquisition Corp. - Right's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Mountain Lake Acquisition Corp. - Right.

Mountain Lake Acquisition Corp. - Right (NASDAQ:MLACR) Stock, Option Chain

Mountain Lake Acquisition Corp. - Right

Biotech

General

RLYB

Rallybio Announces First Dosing In Phase 2 Trial Of RLYB212 For Pregnancy-Related Conditions; PK And Safety Data Expected Q2 2025 And At Delivery Q3 2025

News

Offerings

HYPR

Hyperfine Announces $6M Registered Direct Offering

Mizuho analyst Graig Suvannavejh maintains Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) with a Outperform and raises the price target from $137 to $195.

Price Target

Analyst Ratings

AXSM

Mizuho Maintains Outperform on Axsome Therapeutics, Raises Price Target to $195

Guidance

Ecolab Sees Q1 Adj. EPS $1.47-$1.53 vs. $1.48 Est.; Sees FY25 Adj. EPS $7.42-$7.62 vs. $7.40 Est.

Earnings

Earnings Beats

IPGP

IPG Photonics Q4 2024 Adj. EPS $0.26 Beats $0.21 Estimate, Sales $234.337M Beat $227.403M Estimate

CABA

Cabaletta Bio Announced Updated Data On Resecabtagene Autoleucel To Be Presented At 2025 Conferences; Covers Safety, Translational Data, Clinical Outcomes From First 10 Patients In RESET Program

Benchmark analyst Cody Acree reiterates Tower Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSEM#NASDAQ">TSEM</a>) with a Buy and maintains $60 price target.

Reiteration

TSEM

Benchmark Reiterates Buy on Tower Semiconductor, Maintains $60 Price Target

During the last three months, 11 analysts shared their evaluations of Rockwell Automation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROK#NYSE">ROK</a>), revealing diverse outlooks from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $321.09, along with a high estimate of $350.00 and a low estimate of $240.00. Surpassing the previous average price target of $298.45, the current average has increased by 7.59%.
<img src="https://www.benzinga.com/files/images/story/2025/1739278877_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Rockwell Automation. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joseph O'Dea</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$337.00</td>
<td>$315.00</td>
</tr>
<tr>
<td>Andrew Kaplowitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$350.00</td>
<td>$345.00</td>
</tr>
<tr>
<td>Tommy Moll</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Overweight</td>
<td>$350.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Stephen Tusa</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$240.00</td>
<td>$245.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$285.00</td>
<td>$290.00</td>
</tr>
<tr>
<td>Saree Boroditsky</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$350.00</td>
<td>$290.00</td>
</tr>
<tr>
<td>Andrew Kaplowitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$345.00</td>
<td>$313.00</td>
</tr>
<tr>
<td>Ken Newman</td>
<td>Keybanc</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$345.00</td>
<td>$345.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$290.00</td>
<td>$255.00</td>
</tr>
<tr>
<td>Richard Eastman</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$305.00</td>
<td>$290.00</td>
</tr>
<tr>
<td>Joshua Pokrzywinski</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$335.00</td>
<td>$320.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Rockwell Automation. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Rockwell Automation compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Rockwell Automation's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Rockwell Automation's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ROK/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Rockwell Automation analyst ratings.</a>
<h2>Get to Know Rockwell Automation Better</h2>
With roots tracing back to the early 1900s, Rockwell Automation is the successor to Rockwell International, which spun off its avionics segment in 2001. It is a pure-play industrial automation company that operates through three segments. Its largest segment by revenue, intelligent devices, sells factory floor-level devices such as motors, drives, sensors, relays, and actuators. Its software &amp; control segment sells visualization, simulation, and human-machine interface software and control products such as programmable controllers, computers, and operator terminals. Its smallest segment, lifecycle services, offers digital consulting, engineered-to-order services, and other outsourced services such as remote monitoring, cybersecurity, and asset and plant maintenance and optimization.
<h3>A Deep Dive into Rockwell Automation's Financials</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Negative Revenue Trend: Examining Rockwell Automation's financials over 3 months reveals challenges. As of 30 September, 2024, the company experienced a decline of approximately -20.58% in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Industrials sector.
Net Margin: Rockwell Automation's net margin is impressive, surpassing industry averages. With a net margin of 11.69%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 6.98%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Rockwell Automation's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.12% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a high debt-to-equity ratio of 1.17, Rockwell Automation faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>Analyst Ratings: What Are They?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What Analysts Are Saying About Rockwell Automation Stock

In the preceding three months, 11 analysts have released ratings for Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), presenting a wide array of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Moderna, revealing an average target of $56.45, a high estimate of $99.00, and a low estimate of $34.00. Highlighting a 31.99% decrease, the current average has fallen from the previous average price target of $83.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1739278865_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A clear picture of Moderna's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tim Anderson</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$34.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Salveen Richter</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$51.00</td>
<td>$99.00</td>
</tr>
<tr>
<td>Salveen Richter</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$99.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Cory Kasimov</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$50.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Matthew Harrison</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$38.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Eliana Merle</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$96.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>Tim Anderson</td>
<td>B of A Securities</td>
<td>Announces</td>
<td>Underperform</td>
<td>$41.00</td>
<td>-</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$45.00</td>
<td>$59.00</td>
</tr>
<tr>
<td>Edward Tenthoff</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$69.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Yifeng Liu</td>
<td>HSBC</td>
<td>Announces</td>
<td>Buy</td>
<td>$58.00</td>
<td>-</td>
</tr>
<tr>
<td>Alexandria Hammond</td>
<td>Wolfe Research</td>
<td>Announces</td>
<td>Underperform</td>
<td>$40.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Moderna. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Moderna compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Moderna's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
To gain a panoramic view of Moderna's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/MRNA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Moderna analyst ratings.</a>
<h2>Unveiling the Story Behind Moderna</h2>
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
<h3>Moderna's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Moderna showcased positive performance, achieving a revenue growth rate of 3.81% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Moderna's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.7% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Moderna's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 0.11%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Moderna's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 0.08%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Moderna's debt-to-equity ratio is below the industry average. With a ratio of 0.11, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Significance of Analyst Ratings Explained</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MRNA

Moderna Stock: A Deep Dive Into Analyst Perspectives (11 Ratings)

8 analysts have shared their evaluations of FactSet Research Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDS#NYSE">FDS</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $496.5, with a high estimate of $525.00 and a low estimate of $409.00. Observing a 3.76% increase, the current average has risen from the previous average price target of $478.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1739278853_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of FactSet Research Systems among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jason Haas</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$500.00</td>
<td>$503.00</td>
</tr>
<tr>
<td>Jeffrey Silber</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$518.00</td>
<td>$521.00</td>
</tr>
<tr>
<td>Shlomo Rosenbaum</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$493.00</td>
<td>$469.00</td>
</tr>
<tr>
<td>Ashish Sabadra</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$503.00</td>
<td>$503.00</td>
</tr>
<tr>
<td>Toni Kaplan</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Underweight</td>
<td>$409.00</td>
<td>$373.00</td>
</tr>
<tr>
<td>Ashish Sabadra</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$503.00</td>
<td>$503.00</td>
</tr>
<tr>
<td>Alex Kramm</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$525.00</td>
<td>$485.00</td>
</tr>
<tr>
<td>Jeffrey Silber</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$521.00</td>
<td>$471.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to FactSet Research Systems. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of FactSet Research Systems compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for FactSet Research Systems's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into FactSet Research Systems's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/FDS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on FactSet Research Systems analyst ratings.</a>
<h2>Discovering FactSet Research Systems: A Closer Look</h2>
FactSet provides financial data and portfolio analytics to the Global investment community. The company aggregates data from third-party data suppliers, news sources, exchanges, brokerages, and contributors into its workstations. In addition, it provides essential portfolio analytics that companies use to monitor portfolios and address reporting requirements. Buy-side clients (including wealth and corporate clients) account for 82% of FactSet's annual subscription value. In 2015, the company acquired Portware, a provider of trade execution software. In 2017, it acquired BISAM, a risk management and performance measurement provider. In 2022, it completed its purchase of CUSIP Global Services.
<h3>Understanding the Numbers: FactSet Research Systems's Finances</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: FactSet Research Systems's remarkable performance in 3 months is evident. As of 30 November, 2024, the company achieved an impressive revenue growth rate of 4.88%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 26.38%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 7.69%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 3.7%, the company showcases effective utilization of assets.
Debt Management: FactSet Research Systems's debt-to-equity ratio is notably higher than the industry average. With a ratio of 0.78, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>Analyst Ratings: What Are They?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down FactSet Research Systems: 8 Analysts Share Their Views

Ecolab (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ECL#NYSE">ECL</a>) reported quarterly earnings of $1.81 per share which beat the analyst consensus estimate of $1.79 by 1.12 percent. This is a 16.77 percent increase over earnings of $1.55 per share from the same period last year. The company reported quarterly sales of $4.005 billion which beat the analyst consensus estimate of $3.985 billion by 0.50 percent. This is a 1.71 percent increase over sales of $3.938 billion the same period last year.

Ecolab Q4 2024 Adj. EPS $1.81 Beats $1.79 Estimate, Sales $4.005B Beat $3.985B Estimate

Americans have been praying for lower mortgage rates. They had no idea that a Chinese AI app could help them obtain them.
A knee-jerk selloff in tech stocks on Jan. 27 prompted by a new Chinese AI tool by startup DeepSeek that rivals <a href="https://www.benzinga.com/tech/25/02/43485775/openais-big-rebrand-chatgpt-parent-wants-to-reflect-a-more-organic-future-with-new-logo-typeface">Chat GPT</a> caused some of Silicon Valley&#8217;s most prominent companies to see their stock price plummet overnight. Bond yields also fell that day, and the byproduct of lower bond yields —resulting from bond prices increasing—was to see mortgage rates drop as well.
Don't Miss:
<ul>
<li>Nancy Pelosi Invested $5 Million In An AI Company Last Year — <a href="https://www.benzinga.com/money/elf-labs-nancy-pelosi">Here's How You Can Invest In Multiple Pre-IPO AI Startups With Just $1,000</a></li>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a></li>
</ul>
Although the mortgage rate decline was modest—falling to 6.96%—after the tech stock selloff, the pattern seems to have persisted, as the following week, according to<a href="https://www.freddiemac.com/pmms"> Freddie Mac</a>, it fell again to 6.89%.
&#8220;Home shoppers who already have an offer accepted can take advantage of this reprieve, but I don&#8217;t expect it to mean lasting mortgage rate relief for home shoppers,&#8221;<a href="https://www.realtor.com/news/trends/china-ai-deepseek-tech-stock-mortgage-rate/"> realtor.com</a> Chief Economist Danielle Hale said. &#8220;That will come from broader economic stability and ongoing improvement in inflation.&#8221;
One of the tech titans to hit the worst was AI chip innovator <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/02/43540906/nvidia-stock-remains-analysts-top-pick-deepseek-selloff-is-a-buying-opportunity">Nvidia</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), which saw shares plunge 17% and its market cap drop by $590 billion. However, the fact that DeepSeek still used Nvidia chips to build its AI platform, <a href="https://www.nytimes.com/2025/01/23/technology/deepseek-china-ai-chips.html">according to the New York Times</a> — albeit in fewer numbers than their US counterparts — might have been missed by those who suddenly sold their shares in the company. Ultimately, the US-based chip maker is still the kingmaker regarding AI technology.
Trending: Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a>
<h2 class="wp-block-heading">Why US Tech Stocks Tanked After DeepSeek Debuted</h2>
DeepSeek claims to have built its AI platform for less than behemoths <a href="https://www.benzinga.com/insights/news/25/02/43531004/comparing-meta-platforms-with-industry-competitors-in-interactive-media-amp-services-industry">Meta</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), <a href="https://www.benzinga.com/markets/equities/25/02/43485518/google-ais-search-revenue-matches-traditional-ads-says-alphabet-but-there-is-rising-competition-from-openai-perplexity-deepseek">Google</a>, and Open AI, raising fears that the established AI players were wildly overspending, setting them up for a fall. The concern appeared short-lived as US tech stocks<a href="https://www.usatoday.com/story/money/markets/2025/01/28/wall-street-stock-market-nvidia-rebound-deepseek/77990744007/"> </a>&nbsp;recovered shortly after the initial crash.
After the initial DeepSeek hoopla, the narrative concerning their low-budget creation drew skepticism. Wedbush analyst Dan Ives called it &#8220;likely a fictional story.&#8221; Bill Stein, chief investment officer and co-founder of Primary Digital Infrastructure, also questioned DeepSeek&#8217;s budgetary claims.
"I don&#8217;t see how 4-year-old processors are going to compete with the newest processors from Nvidia,&#8221; he told<a href="https://www.costar.com/article/1828444666/cheap-ai-could-be-good-for-real-estate#"> CoStar News.</a> &#8220;It doesn&#8217;t make sense.&#8221;
Trending: Built on the trusted network of Fortune 500 companies, <a href="https://www.benzinga.com/money/web3-enabler-the-most-boring-blockchain-company-partners-with-salesforce">this blockchain company partners with Salesforce to uproot lengthy and expensive B2B transactions, and you can invest with just $100.</a>
<h2 class="wp-block-heading">How Will DeepSeek Affect Interest Rates?</h2>
Not much more than they already have. The Fed&#8217;s recent move to leave rates unchanged was not a reflection of the turmoil with tech stocks but a response to the general uncertainty about the economy and inflation. Certainly, barring a dramatic change, as seen during the financial crash, the Fed has a policy of not reacting to the stock market.
<h2 class="wp-block-heading">The Wider Ramifications of DeepSeek</h2>
Power stocks have been an unlikely victim of DeepSeek&#8217;s arrival. Media reports said that the Chinese generative AI model was trained using far less power than its American competitors, which directly affected the price of power stocks that were previously soaring thanks to increased data center usage.
See Also: ‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a>
Unlike the tech stock drop-off, the ramifications of requiring less power than initially anticipated could be longer-lasting. A <a href="https://buildings.lbl.gov/news/berkeley-lab-report-evaluates-increase-electricity-demand-data-centers#:~:text=Among%20the%20report's%20key%20findings,total%20U.S.%20electricity%20by%202028.">recent report</a> from Lawrence Berkeley National Laboratory found that data centers could consume between 6.7% and 12% of total US electricity by 2028, compared with 4.4% in 2023.&nbsp;
&#8220;I continue to think that investing very heavily…is going to be a strategic advantage over time,&#8221; Meta CEO Mark Zuckerberg said on the company's earnings call late last month. &#8220;It&#8217;s possible that we&#8217;ll learn otherwise at some point, but I just think it&#8217;s way too early to call that.&#8221;
Read Next:
<ul>
<li>According to Juniper Research, the total value of B2B cross-border payments stored on the blockchain is projected to exceed $4.4 trillion — <a href="https://www.benzinga.com/money/web3-enabler-future-of-enterprise-transactions">Join the first company to bring blockchain payments to Salesforce early with just $100.</a></li>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
</ul>

Real Estate

NVDA

Will DeepSeek Create Deep Cuts In Mortgage Rates? Has Chinese AI Innovator Disrupted Silicon Valley's Tech Titans, Or Is It Just A Temporary Blip?

In the last three months, 7 analysts have published ratings on Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>), offering a diverse range of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $76.57, with a high estimate of $88.00 and a low estimate of $70.00. Observing a downward trend, the current average is 0.56% lower than the prior average price target of $77.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1739278834_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The perception of Incyte by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Lebowitz</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$88.00</td>
<td>$97.00</td>
</tr>
<tr>
<td>Stephen Willey</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$77.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Leonid Timashev</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$70.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Derek Archila</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$70.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Nicholas Holowko</td>
<td>UBS</td>
<td>Announces</td>
<td>Neutral</td>
<td>$77.00</td>
<td>-</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$74.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$80.00</td>
<td>$72.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Incyte. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Incyte compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Incyte's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Incyte's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/INCY/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Incyte analyst ratings.</a>
<h2>Unveiling the Story Behind Incyte</h2>
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
<h3>A Deep Dive into Incyte's Financials</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Incyte's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 23.81%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Incyte's net margin excels beyond industry benchmarks, reaching 9.36%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Incyte's ROE stands out, surpassing industry averages. With an impressive ROE of 3.45%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 2.2%, the company showcases effective utilization of assets.
Debt Management: Incyte's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.01.
<h2>Analyst Ratings: Simplified</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

INCY

What Analysts Are Saying About Incyte Stock

In the latest quarter, 5 analysts provided ratings for Edgewell Personal Care (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPC#NYSE">EPC</a>), showcasing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Edgewell Personal Care, revealing an average target of $34.6, a high estimate of $37.00, and a low estimate of $32.00. Observing a downward trend, the current average is 8.95% lower than the prior average price target of $38.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1739278820_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Edgewell Personal Care. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chris Carey</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$35.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Dara Mohsenian</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$32.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Lauren Lieberman</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$33.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Peter Grom</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$36.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Chris Carey</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$37.00</td>
<td>$42.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Edgewell Personal Care. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Edgewell Personal Care compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Edgewell Personal Care's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Edgewell Personal Care's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/EPC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Edgewell Personal Care analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind Edgewell Personal Care</h2>
Edgewell Personal Care Co is a personal-care company. The operating segments of the company include Wet Shave, Sun and Skin Care and Feminine Care. Some of the brands offered by the company include Edge, Skintimate, Personna, Schick, Carefree, Playtex, Banana Boat and Hawaiian Tropic. It derives a majority of its revenue from the United States.
<h3>Breaking Down Edgewell Personal Care's Financial Performance</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Edgewell Personal Care's revenue growth over a period of 3 months has faced challenges. As of 30 September, 2024, the company experienced a revenue decline of approximately -3.09%. This indicates a decrease in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Consumer Staples sector.
Net Margin: Edgewell Personal Care's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.7% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Edgewell Personal Care's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.56% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Edgewell Personal Care's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 0.24%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Edgewell Personal Care's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.82.
<h2>The Significance of Analyst Ratings Explained</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 5 Analyst Projections For Edgewell Personal Care

Looking into the current session, Freeport-McMoRan Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCX#NYSE">FCX</a>) shares are trading at $38.06, after a 1.04% drop. Over the past month, the stock fell by 2.26%, but over the past year, it actually went up by 3.39%. With questionable short-term performance like this, and great long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio. 

<img src="https://www.benzinga.com/files/images/story/2025/1739278812_0.png" alt="Past Year Chart" />

<h3>Freeport-McMoRan P/E Compared to Competitors</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of 28.97 in the Metals &amp; Mining industry, Freeport-McMoRan Inc. has a higher P/E ratio of 29.58. Shareholders might be inclined to think that Freeport-McMoRan Inc. might perform better than its industry group. It's also possible that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1739278812_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

Markets

Price Over Earnings Overview: Freeport-McMoRan

Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on Enanta Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>) in the last three months.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $19.25, along with a high estimate of $21.00 and a low estimate of $18.00. Experiencing a 17.2% decline, the current average is now lower than the previous average price target of $23.25. 
<img src="https://www.benzinga.com/files/images/story/2025/1739278812_0_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The perception of Enanta Pharma by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ed Arce</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$18.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Ed Arce</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$18.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Brian Skorney</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$20.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Roy Buchanan</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$21.00</td>
<td>$22.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Enanta Pharma. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Enanta Pharma compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Enanta Pharma's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Enanta Pharma's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ENTA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Enanta Pharma analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About Enanta Pharma</h2>
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
<h3>Financial Milestones: Enanta Pharma's Journey</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Enanta Pharma's revenue growth over a period of 3 months has faced challenges. As of 30 September, 2024, the company experienced a revenue decline of approximately -22.84%. This indicates a decrease in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Enanta Pharma's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -197.32%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Enanta Pharma's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -20.76%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Enanta Pharma's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -7.43%, the company showcases efficient use of assets and strong financial health.
Debt Management: Enanta Pharma's debt-to-equity ratio is notably higher than the industry average. With a ratio of 0.43, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>Analyst Ratings: Simplified</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ENTA

The Analyst Verdict: Enanta Pharma In The Eyes Of 4 Experts

Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:<a href="https://www.benzinga.com/stock/ACON#NASDAQ">ACON</a>, ACONW)), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its 24th issued US patent. Whereas previous issued patents in the Aclarion portfolio limit the use of propionic acid (PA) identification by magnetic resonance spectroscopy (MRS) to the disc, this new patent expands Aclarion's ability to use MRS to identify PA throughout the body to identify potential sources of infection and pain.

Government

Regulations

ACON

Aclarion Secures 24th US Patent, Expanding Use of Biomarkers to Detect Pain and Infections Across the Body

ParaZero Technologies Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRZO#NASDAQ">PRZO</a>) (the "company" or "ParaZero"), an aerospace company focused on safety systems for commercial unmanned aircrafts and defense Counter UAS systems, announced today that its SafeAir systems, integrated with the DJI Matrice 350, DJI Mavic 3T and DJI Mavic 3E, have successfully achieved CE Class C5 compliance. This achievement marks a significant advancement in drone safety and regulatory readiness, particularly within the European market.
The CE Class C5 certification is crucial for compliance with the European Union Aviation Safety Agency (EASA) regulations, especially for operators navigating the complex Specific Operations Risk Assessment (SORA) process. By meeting these stringent requirements, ParaZero's SafeAir systems simplify the regulatory pathway for drone operators, enabling them to conduct missions in an urban environment, with greater confidence, efficiency, and safety.
Achieving CE Class C5 compliance ensures that drone operators can now perform operations under the popular Standard Scenario STS-01, which permits drone flights in densely populated urban areas with controlled ground spaces. This reduces the need for extensive documentation and lengthy approval processes, significantly accelerating deployment timelines for commercial and defense drone missions.

PRZO

ParaZero's SafeAir Systems Achieve CE Class C5 Compliance, Boosting Drone Safety and Urban Flight Operations in Europe

The most oversold stocks in the materials sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Albemarle Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALB#NYSE">ALB</a>)</h3>
<ul>
<li>On Jan. 28, Truist Securities analyst Peter Osterland initiated coverage on Albemarle with a Hold rating and announced a price target of $96. The company' stock fell around 18% over the past month and has a <a href="https://www.benzinga.com/quote/ALB">52-week low of $71.97</a>.</li>
<li>RSI Value: 25.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>ALB Price Action: Shares of Albemarle fell 2.9% to close at $75.14 on Monday.</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent021125&amp;t=be2bearmibe3na1">ALB news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent021125&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="807" height="782" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11040024/image-2-23.png" alt="" class="wp-image-776084" style="width:504px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11040024/image-2-23.png 807w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11040024/image-2-23-300x291.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11040024/image-2-23-768x744.png 768w" sizes="(max-width: 807px) 100vw, 807px" /></a></figure>
<h3 class="wp-block-heading">Purecycle Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCT#NASDAQ">PCT</a>)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</h3>
<ul>
<li>On Feb. 5, PureCycle announced a $33 million financing transaction. PureCycle CEO Dustin Olson said, &#8220;We&#8217;re excited to bring on a new partner like Pleiad Investment Advisors. We are making material progress with trials and are continuing to pursue commercial success in fiber and other applications.&#8221; The company's stock fell around 12% over the past month and <a href="https://www.benzinga.com/quote/PCT">has a 52-week low</a> of $4.26.</li>
<li>RSI Value: 28.5</li>
<li>PCT Price Action: Shares of Purecycle Technologies fell 2.1% to close at $8.48 on Monday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent021125&amp;t=be2bearmibe3na1">PCT stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent021125&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="907" height="835" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11040133/image-87.png" alt="" class="wp-image-776085" style="width:539px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11040133/image-87.png 907w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11040133/image-87-300x276.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11040133/image-87-768x707.png 768w" sizes="(max-width: 907px) 100vw, 907px" /></a></figure>
<h3 class="wp-block-heading">Northern Technologies International Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTIC#NASDAQ">NTIC</a>)</h3>
<ul>
<li>Northern Technologies International is expected to release its fiscal 2025 first-quarter financial results on Thursday, Jan. 9, before the opening bell. The company's stock fell around 16% over the past month and has a 52-week<a href="https://www.benzinga.com/quote/NTIC"> low of $11.15</a>.</li>
<li>RSI Value: 27.6</li>
<li>NTIC Price Action: Shares of Northern Technologies International fell 1% to close at $11.16 on Monday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential breakout in <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent021125&amp;t=be2bearmibe3na1">NTIC shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent021125&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="898" height="847" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11040227/image-88.png" alt="" class="wp-image-776087" style="width:546px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11040227/image-88.png 898w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11040227/image-88-300x283.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11040227/image-88-768x724.png 768w" sizes="(max-width: 898px) 100vw, 898px" /></a></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43593480/wall-streets-most-accurate-analysts-give-their-take-on-3-real-estate-stocks-with-over-6-dividend-yields-2">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Real Estate Stocks With Over 6% Dividend Yields</a></li>
</ul>

Long Ideas

Pre-Market Outlook

Trading Ideas

NTIC

Top 3 Materials Stocks Which Could Rescue Your Portfolio This Quarter

WIIM

FLNC

Fluence Energy shares are trading lower after the company reported worse-than-expected Q1 financial results and issued FY25 revenue guidance below estimates.

Comments

Mountain Lake Acquisition Corp. - Right

Mountain Lake Acquisition Corp. - Right (MLACR) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga